INTRODUCTION {#sec1-1}
============

After decades of serious obsession with the modern medicinal system, people have started considering the ancient healing systems such as Ayurveda, Siddha, and Unani, because of the adverse effects associated with synthetic drugs. Ancient Indian literature incorporates a remarkably broad definition of medicinal plants and considers 'all' plant parts to be potential sources of medicinal substances.\[[@ref1]\] In India, a small proportion of wild plants have been investigated both phytochemically and pharmacologically.\[[@ref2]\]

*Achyranthes aspera* Linn. (Amaranthaceae) is a small erect annual shrub found distributed throughout the tropical and subtropical regions. It is commonly found in India, Baluchistan, Sri Lanka, tropical Asia, Africa, Australia, and America.\[[@ref3]\] This wild tropical plant is known by different names such as *Chirchita* (Hindi), *Apamarga* (Sanskrit), *Aghedi* (Gujarati), *Apang* (Bengali), *Nayurivi* (Tamil), *Kalalat* (Malyalam),\[[@ref4]\] and *Agadha* (Marathi) in India.

The plant is reported to have several medicinal properties and used as emmenagogue, purgative, diuretic, antimalarial, antihyperlipidemic, estrogenic, antileprotic, antispasmodic, cardiotonic, antibacterial, and antiviral agents in traditional systems of medicine. It is also used as antiasthmatic antitussive and in the treatment of snakebite, hydrophobia, urinary calculi, rabies, influenza, otorrhoea, piles, bronchitis, diarrhea, renal dropsies, gonorrhea, and abdominal pain.\[[@ref5]--[@ref8]\]

Earlier phytochemical studies reported that it contains saponins, alkaloids (betaine, achyranthine), amino acids, steroids (stigmasterol), triterpenoids (oleanolic acid and its glucoside), phenolic content (indole acetic acid oxidase), and flavonoids It has also been reported to have antiarthritic, antirheumatic activity as per folklore practice.\[[@ref9]\] The present study was therefore designed to corroborate this claim of anti-inflammatory potential of the plant extracts on different phases of inflammation and to further deduce the phytochemicals responsible for this potential.

MATERIALS AND METHODS {#sec1-2}
=====================

Collection of plant material and preparation of extract {#sec2-1}
-------------------------------------------------------

Plant material was collected from local areas of Pune, authenticated by Botanical Survey of India, Pune (MRZAA1 date: 16/9/09). Leaves and whole plant were pulverized separately using an electrical grinder and extracted with distilled water at 100°C for 4 h, centrifuged at 5,000 g for 15 min, and filtered using Whatman No.1 filter paper. The filtrate was vacuum evaporated to yield 9.4% leaf and 6.6% whole plant extract, respectively.

Phytochemical study {#sec2-2}
-------------------

Both aqueous extracts of *A. aspera* (AEAA) were subjected to preliminary phytochemical analysis with reference to standard protocol for the detection of various constituents such as alkaloids, glycosides, saponins, steroids/triterpenoids, tannins, flavonoids, carbohydrates, proteins and amino acids.\[[@ref10]\]

High Performance Thin Layer Chromatogram (HPTLC) profile {#sec2-3}
--------------------------------------------------------

AEAA 29.2 mg was dissolved in 29.2 mL of methanol and samples of 5 μL, 10 μL, and 20 μL were applied as 8 mm-wide bands, under a continuous flow of nitrogen, using a CAMAG LINOMATE V automatic sample applicator. The sample was applied with a 100 μL syringe (Hamilton, Bonaduz, Switzerland) at a constant application rate of 0.1 μL/s and the distance between adjacent bands was retained at 15 mm. The plate was developed using the solvent system chloroform: toluene: methanol (4:4:1 \[v/v\]) and scanned by a densitometer (CAMAG) at 254 nm.

Experimental animals {#sec2-4}
--------------------

Swiss albino mice of either sex (25-30 g) were used for the study. The animals were housed under uniform standard laboratory conditions. They were provided with food and water *ad libitum*. The animals were acclimatized for 7 days before experiments were performed. The experimental protocol was approved by Institutional Animal Ethics Committee.

Acute oral toxicity test {#sec2-5}
------------------------

The acute oral toxicity study for AEAA was carried out according to OECD guidelines 423.\[[@ref11]\] Swiss albino mice were fasted overnight, with water also being withheld. The AEAA was administered at a dose of 2,000 mg/kg. Animals were observed individually during the first 30 min and periodically during 24 h, with special attention given during the first 4 h and daily thereafter, for a total of 14 days.

Anti-inflammatory study {#sec2-6}
-----------------------

Anti-inflammatory activity of the AEAA was studied using the carrageenan-induced left hind paw edema (Plethysmographic method). Animals were grouped with 6 animals in each group and received treatment as control (NS), standard, i.e. Diclofenac 10 mg/kg, aqueous extracts of *A. aspera* leaves (AEAAL) 400 mg/kg, AEAAL 800 mg/kg, aqueous extracts of *A. aspera* whole plant (AEAAW) 400 mg/kg, and AEAAW 800 mg/kg intraperitoneally. One hour after administration of drug/extracts, 0.01 mL of 1% carrageenan (Sigma Aldrich, Chemical) suspension was injected subcutaneously into the plantar surface of the left hind paw. The volumes of albino mouse hind paws in the test, control, and standard groups were measured using a Plethysmometer (Make: Ugobasile) at 0 min, 45 min, 2 h, 4 h, and 5 h after the induction of inflammation, and edema was expressed as an increase in paw volume due to carrageenan injection.\[[@ref12]\]

Statistical analysis {#sec2-7}
--------------------

Data was analyzed using Vassarstats software. Analysis was performed using ANOVA followed by Dunnett\'s test. *P* \<0.05 was considered significant. Percent inhibition in paw edema was calculated using the following formula:

\% inhibition = 100 (1 -- *V*~t~/*V*~c~), where *V*~c~ = edema volume in control and *V*~t~ = edema volume in test groups.

RESULTS {#sec1-3}
=======

Acute oral toxicity test {#sec2-8}
------------------------

Acute toxicity study did not reveal any signs or symptoms of toxicity or mortality during the observation period, at the dose of 2,000 mg/kg. Hence, the starting dose selected for anti-inflammatory evaluation was 1/5^th^ of 2,000 mg/kg (i.e., 400 mg/kg).

Phytochemical analysis {#sec2-9}
----------------------

Primary phytochemical screening of extracts determined the presence of alkaloids, glycosides, tannins, saponins, carbohydrates, and flavonoids as major constituents in AEAA; triterpenoids, however, were detected only in AEAAW, whereas steroids were found absent in both the extracts \[[Table 1](#T1){ref-type="table"}\]. HPTLC at 254 nm showed the presence of 14 components in AEAAW and 12 in AEAAL with their retardation factor (*R*~f~) values. Component with *R*~f~ 0.20, 0.23, 0.35, 0.45 0.58, 0.65, and 0.86 matched with standards \[[Figure 1](#F1){ref-type="fig"}\]. Component numbers 2 and 5 showed maximum concentration with low *R*~f~, i.e. 0.03 and 0.17, respectively. These unknown components appear to be alkaloids and saponins, since volatile plant components such as flavonoids and phenolic content have higher *R*~f~ with less solubility compared to alkaloids and saponins, which have maximum and intermediate solubility, respectively, in all three solvents, with least volatility and low *R*~f~.

###### 

Preliminary phytochemical analysis of *Achyranthes aspera*
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![Optimized HPTLC chromatogram of (a) Aqueous extracts *Achyranthes aspera* whole plant (b) Aqueous extracts *Achyranthes aspera* leaves at 254 nm](ASL-31-202-g002){#F1}

Anti-inflammatory study {#sec2-10}
-----------------------

The results obtained are summarized in [Table 2](#T2){ref-type="table"}. As shown, standard and all the doses of AEAA exhibited significant anti-inflammatory activity at 2 h, 4 h, and 5 h (*P* \< 0.01, *P* \< 0.001) with marked percentage inhibition in paw edema compared to control at each time point measured; 800 mg/kg dose of both the extracts showed stronger activity in this regard. Maximum percentage inhibition in paw edema was observed at 4 h (35.71-54.76%). When this activity was compared to standard, 800 mg/kg in the AEAAW group exhibited significantly stronger anti-inflammatory activity (*P* \< 0.01, *P* \< 0.001). All extract groups, except for the 400 mg/kg leaf extract group, exhibited significant anti-inflammatory activity in 45 min (*P* \< 0.01, *P* \< 0.001), which was not observed with the standard group.

###### 

Effect of aqueous extracts of *Achyranthes aspera* on carrageenan-induced mouse paw edema

![](ASL-31-202-g003)

DISCUSSION {#sec1-4}
----------

Carrageenan-induced edema serves as an index of acute inflammatory changes, determined from differences in the paw volume measured immediately after carrageenan injection and then periodically. It is believed to be biphasic; the first phase (1 h) involves the release of serotonin histamine and kinin and the second phase (over 1 h) is mediated by prostaglandins and cyclooxygenase products.\[[@ref13]\]

In the present study, 400 and 800 mg/kg of AEAA showed maximum inhibition in paw edema at 4 h (35.71-54.76%). A similar study performed by Vijaya Kumar *et al*. showed 32-40.5% inhibition with dose range 50-200 mg/kg.\[[@ref2]\] Since acute toxicity study confirmed the toxic dose of AEAA to be more than 2,000 mg/kg, we have evaluated higher doses of AEAA and our study revealed a dose-dependent increase in anti-inflammatory activity. ED50 for AEAAL was found to be 1,200 mg/kg and 562 mg/kg for AEAAW \[[Figure 2](#F2){ref-type="fig"}\], which is reflected in the results. AEAAW was found to exhibit stronger anti-inflammatory activity than AEAAL.

![Effect of aqueous extracts Achyranthes aspera leaves (AEAAL) and aqueous extracts Achyranthes aspera whole plant (AEAAW) on carrageenan induced paw edema. ED50 log dose = 3.09 and 2.75 for AEAAL and AEAAW respectively. Dose = 1200 mg/kg for AEAAL and 562 mg/kg bodyweight for AEAAW](ASL-31-202-g004){#F2}

For validity demonstration of the carrageenan-induced paw edema, Diclofenac 10 mg/kg was used as standard, and as expected it significantly (*P* \< 0.01, *P* \< 0.001) reduced edema of phase 2, i.e. at 2 h and 4 h. Comparable anti-inflammatory activity was observed with both extracts against phase 2; however, both the extracts (except for AEAAL 400 mg/kg may be due to inadequate systemic bioavailability at this dose) exhibited significant anti-inflammatory activity against phase 1 response as well; this indicates it also inhibits serotonin- and histamine-induced inflammatory reaction. From these findings, it can be hypothesized that the anti-inflammatory activity of AEAA is due to the inhibition of release of serotonin and histamine from mast cells and by inhibition of the cyclooxygenase pathway. This mode of action supports its use in asthma/allergy and arthritis treatment in traditional medicine.\[[@ref6]\]

On phytochemical screening, AEAA showed the presence of alkaloids, saponins, and flavonoids as major constituents in AEAA, which is in agreement with the study conducted by Sutar *et al*.\[[@ref14]\] however, triterpenoids are revealed as additional constituents in AEAAW and this may be the reason for the stronger anti-inflammatory activity of the extract. HPTLC confirmed the presence of gallic acid, luteolin, apigenin, p-coumaric acid, chlorogenic acid, ursolic/oleanolic acid, and quercetin in AEAA. Hence, the significant anti-inflammatory activity of AEAA could be due to the presence of flavonoids, alkaloids, and saponins, which may exert predominant inhibition of inflammatory mediators from phlogogenic stimuli and potential inhibitory action on exudate formation.\[[@ref9]\] Further studies to purify, isolate, and standardize the phytoconstituents for making them available for human use are warranted. This evaluation could be an important finding globally, as inflammation has become a common disease condition with "poor availability of safe drug therapies".

CONCLUSION {#sec1-5}
----------

Both AEAA exhibit promising anti-inflammatory activity, which is attributed to flavonoids, alkaloids, saponins, and triterpenoids phytoconstituents found in extracts. This abundantly available plant may serve as an important addition in therapeutic armamentarium of chronic inflammatory diseases such as arthritis.
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